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ABSTRACT 
Camptothecin, Doxorubicin, Paclitaxel, Vincristine, and Etoposide are the naturally occurring anti-cancer drugs that are analyzed in 
this analysis. It is found that these compounds can be developed as nanomedicine. It has been determined from analyses that 
nanoparticles are useful in targeted drug delivery to address some of the innate issues. However, there are certain limitations that are 
found in nanomedicine. There is a need for more research to develop effective drugs in the future. A more detailed analysis of the 
same has been done in the following.  
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INTRODUCTION 
Nanoparticles have more surfaces to volume ratio. These 
nanoparticles are found to revolutionize drug delivery.
1
 
This is because the drugs target the viruses and tumors 
and they are found to not affect the healthy tissue.
2,3
 The 
bioavailability of the particles is found to be the reason 
for the Nanomedicine to gain precedence. 
Natural product is one of the best sources for procuring 
drugs and drug leads.
4-6
 From the year 1940 onwards, 
131 drugs out of 175 small molecule anticancer drugs are 
found to be based on the natural product.
7
 This is owing 
to the fact that the natural products are found to have 
diversity in their physical structure and have chemical 
diversity. 40% of the chemical scaffolding is found in 
natural products.
8,9
 One of the most important reasons 
for considering natural products is that they are 
optimized evolutionarily as a drug-like molecule.
10-12
 
This is based on the natural products and these drugs are 
found to occupy the same molecular volume. 
13
 
Some of the nanoparticles that have been developed from 
the natural products are discussed in the following. 
Camptothecin  
Camptothecin is found to plant alkaloid that is initially 
isolated from Camptotheca acuminate. Camptothecin is 
found in the bark, leaves, and stem in the Chinese happy 
tree. Camptotheca acuminate is a native breed to 
China.
14,15
 These are considered to be important for the 
anticancer properties of Camptothecin.
16-18
 This is 
considered to be the traditional medicine that has been 
used for many centuries. This Camptothecin compound 
is found to have an important role in curing of a number 
of diseases including Nanomedicine treatment for 
cancer. This Camptothecin compound is found to halt the 
cell during the S phase mitosis. It is found to have a 
nanomolar potency to address the issues of cytotoxicity 
against the human tumor cell lines such as HT29, LOX 
to name a few. In combination with the TNF, it is found 
to induce apoptosis. A number of feasible drugs that are 
developed from the Camptothecin analogs are used in the 
development of anti-cancer drugs. Some of them are 
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topotecan and irinotecan.
19,20
 These have been 
commercially sold as anti-cancer drugs and in 
chemotherapy 
21
 These compounds are now being used 
in Nanomedicine. They are found to have long 
circulation half-lives and localize the tumor cells. The 
nanoparticles address the tumor cells only and release the 
CPT and cause them to disassemble the individual 
polymer chains.
22
 These are found to be smaller and 
cleared renally. IT-101 is one such drug that is currently 
investigated.  Hence, this compound with a lot of 
potentials is found to originate from natural sources. Its 
complete potential in nanomedicine is yet to be utilized 
completely.  
Etoposide  
Etoposide is a compound that is extracted from the 
Podophyllum hexandrum. It is difficult to grow this 
plant. Owing to this, it was found that they can transfer 
the enzyme producing gene from P. hexandrum to 
Nicotiano benthamiana. This is a tobacco-like plant that 
is easier to grow. The engineered plant is found to 
produce only nanograms of etoposide aglycone as a 
precursor to Etoposide The prolific growth of the yeast 
cell can lead to better production. Etoposide is anti-
cancer chemotherapy drug. This drug is a plant alkaloid 
and it functions as a topoisomerase II inhibitor. In the 
current times, it is used as a semisynthetic derivative of 
podophyllotoxin that is found to exhibit antitumor 
activity. The Etoposide inhibit DNA is found and is 
found to form a complex with the topoisomerase II and 
DNA.
23-25
 The complex is used to induce the break in the 
double stranded DNA and is found to prevent repair of 
the topoisomerase II binding. The accumulated then 
breaks the DNA into the mitotic phase of cell division. 
This eventually causes apoptosis. This then enters into 
the G2 and S phases of cell cycle. Currently, the 
feasibility of administering the medicine in the form of 
nanoparticles is being studied.
26
 The complete potential 
of the Etoposide is yet to be harnessed completely.   
Vincristine  
Vincristine is a vinca alkaloid that is isolated from the 
Vinca Rosea. It has been marketed under many brand 
names. These are found in many formulations. This is 
used in the treatment of acute leukemia, Hodgkin's 
disease, malignant lymphoma and acute erythraemia. 
This vincristine sulfate is used as a part of the 
polychemotherapy as it stems from the lack of significant 
bone–marrow suppression. It has a unique clinical 
toxicity. This inhibits the mitosis at the metaphase stage 
that stems from the interaction with the tubulin. They 
interfere with the amino acid, glutathione metabolism, 
calmodulin-dependent Ca2+- or transport the ATPase 
activity or impact the cellular respiration and lipid 
biosynthesis. Currently, the lower solubility of the 
compound is causing a detrimental impact. This has 
impeded the process of nanomedicine. A number of 
clinical trials are being undertaken to understand the 
impact of the compound. 
27
 
Paclitaxel  
Paclitaxel is one of the compounds for cancer drug in the 
United States. This is found to be derived from the bark 
of the Taxus brevifolia. It is used in the treatment of 
Kaposi sarcoma and a number of cancers.(28-30) In this, 
the complex of α, β tubulins subunits along with 
Paclitaxel is used to correct the issues in mitotic spindle 
assembly, cell division, and chromosome 
segregation.
31,32
 This medicinal compound is used in 
Nanomedicine. The encapsulation of Paclitaxel is found 
to be biodegradable and has non-toxic Nano-delivery 
systems that reduce the toxicity of the company and 
increases the circulation half-life. It has found to yield a 
better result. This is also found in improved 
pharmacokinetic profiles. Paclitaxel along with the 
albumin-bound nanoparticles is used as a commercial 
medicine to treat the metastatic breast cancer. This drug 
is currently being used for the treatment of breast cancer 
on a commercial scale. This is one of the few 
nanomedicine drugs that have managed to address all the 
issues. 
33
 There are a number of novel paclitaxel 
nanoparticles that are current being analyzed.  
Doxorubicin 
Doxorubicin is found to be extracted from the 
anthracycline antibiotic that is cytotoxic and isolated 
from the Streptomyces peucetius cultures. These 
compounds are found to bind to the nucleic acid based 
on the specific intercalation of the planar antracyanine 
nucleus along with the double-helical structure of the 
DNA. It is found to impede the growth of the Cancer 
cells in the body.
34
 The doxorubicin blocks the function 
of the enzyme topoisomerase 2. This is needed by the 
cancer cells to proliferate.
35-37
 Some of the factors that 
are considered in this situation are the efficacy of the 
drug based on the exposure of the tissue. The commerce 
and the toxicity are some of the other factors that are 
considered.
38
 There has been an improved 
comprehension of the heterogeneity of clinical cancers 
and its biological factors. There is a transition that has 
been observed in the case of formulation-driven research 
to it being disease driven development. The 
nanomedicine needs to be developed and the potential 
needs to be fully harnessed.  
SUMMARY 
Camptothecin, Doxorubicin, Paclitaxel, Vincristine, and 
Etoposide are some of the naturally occurring anti-cancer 
drugs that are discussed in this analysis. The mechanism 
of action, sources of the compounds and the limitation 
during commercial production of the compounds are 
discussed. From this, a number of insights are gained. 
These are natural medicines and they are found to be 
optimized evolutionarily as a drug-like molecule that 
makes it feasible for the commercial production of the 
compounds. These medicines are mostly administered as 
chemotherapy drugs. These medicines are found to have 
the potential to be administered as nanomedicine into the 
body. However, its complete potential is yet to be 
harnessed. Each of these five compounds is found to be 
naturally occurring and has a number of properties to 
impede the growth of the anti-cancer cells. In the case of 
nanomedicine, there can be targeted drug delivery and 
the toxicity of the medicine can be prevented in this 
process. There are a number of ongoing clinical trials 
that are being undertaken to commercially produce the 
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compounds on a large scale. To conclude, the complete 
potential of the naturally occurring compounds that can 
be used as nanomedicines is yet to be harnessed. 
REFERENCES 
1. Hamidi M, Azadi A, and Rafiei P. Hydrogel nanoparticles in drug 
delivery. Advanced drug delivery reviews. 2008, 60: 1638-1649 
2. Cheng X. Developing organic and inorganic nanomedicine for 
cancer therapy. Journal of Drug Delivery and Therapeutics. 
2017, 7(3): 1-4 DOI: 10.22270/jddt.v7i2.1367 
3. Cheng X, and Lee R J. The role of helper lipids in lipid 
nanoparticles (LNPs) designed for oligonucleotide delivery. Adv 
Drug Deliv Rev. 2016, 99: 129-137; doi: 
10.1016/j.addr.2016.01.022. 
4. Cheng X, Liu Q, Li H, Kang C, Liu Y, Guo T, et al. Lipid 
Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer 
Against Bcl-2 for Treatment of Lung Cancer. Pharm Res. 2017, 
34: 310-320; doi: 10.1007/s11095-016-2063-5. 
5. Duan Y, Pei K, Cai H, Tu S, Cheng X, Zhang Z, et al. Strategy of 
integrated evaluation on treatment of traditional Chinese 
medicine as ‘interaction of system to system’and establishment of 
novel fuzzy target contribution recognition with herb-pairs, a case 
study on Astragali Radix-Fructus Corni. Molecular and Cellular 
Endocrinology. 2016, 434: 219-237 
6. Duan Y, Pei K, Cai H, Tu S, Zhang Z, Cheng X, et al. Bioactivity 
evaluation-based ultra high-performance liquid chromatography 
coupled with electrospray ionization tandem quadrupole-time-of-
flight mass spectrometry and novel distinction of multi-
subchemome compatibility recognition strategy with Astragali 
Radix-Fructus Corni herb-pair as a case study. Journal of 
pharmaceutical and biomedical analysis. 2016, 129: 514-534 
7. Liu Z, Jiao Y, Wang Y, Zhou C, and Zhang Z. Polysaccharides-
based nanoparticles as drug delivery systems. Advanced drug 
delivery reviews. 2008, 60: 1650-1662 
8. Sun Y, and Kang C. Self-Assembly of Peptides into Hydrogel. 
Journal of Organic & Inorganic Chemistry. 2016,  
9. Sun Y, Kang C, Liu F, and Song L. Delivery of Antipsychotics 
with Nanoparticles. Drug Development Research. 2016, 77: 393-
399 
10. Sun Y, Kang C, Yao Z, Liu F, and Zhou Y. Peptide-Based Ligand 
for Active Delivery of Liposomal Doxorubicin. Nano LIFE. 
2016, 6: 1642004 
11. Sun Y, Kang C, Zhang A, Liu F, Hu J, Zhong X, et al. Co-
delivery of dual-drugs with nanoparticle to overcome multidrug 
resistance. European Journal of BioMedical Research. 2016, 2: 
12-18 
12. Waller A P, George M, Kalyanasundaram A, Kang C, Periasamy 
M, Hu K, et al. GLUT12 functions as a basal and insulin-
independent glucose transporter in the heart. Biochimica et 
Biophysica Acta (BBA)-Molecular Basis of Disease. 2013, 1832: 
121-127 
13. Soppimath K S, Aminabhavi T M, Kulkarni A R, and Rudzinski 
W E. Biodegradable polymeric nanoparticles as drug delivery 
devices. Journal of controlled release. 2001, 70: 1-20 
14. Hsiang Y-H, Hertzberg R, Hecht S, and Liu L. Camptothecin 
induces protein-linked DNA breaks via mammalian DNA 
topoisomerase I. Journal of Biological Chemistry. 1985, 260: 
14873-14878 
15. Li Q-Y, Zu Y-G, Shi R-Z, and Yao L-P. Review camptothecin: 
current perspectives. Current medicinal chemistry. 2006, 13: 
2021-2039 
16. Kang C, Qin J, Osei W, and Hu K. Regulation of protein kinase 
C-epsilon and its age-dependence. Biochemical and Biophysical 
Research Communications. 2017, 482: 1201-1206 
17. Kang C, Sun Y, Wang M, and Cheng X. Nanosized camptothecin 
conjugates for single and combined drug delivery. European 
Journal of BioMedical Research. 2016, 2: 8-14 
18. Kang C, Sun Y, Zhu J, Li W, Zhang A, Kuang T, et al. Delivery 
of Nanoparticles for Treatment of Brain Tumor. Current Drug 
Metabolism. 2016, 17: 745-754 
19. Li H, Cheng X, Liu Y, Lee Y B, Kim D J, Ahn C-h, et al. Folate 
receptor-targeted lipid coated albumin nanoparticles (F-LCAN) 
for therapeutic delivery of RX-0201 (Archexin®), an antisense 
oligonucleotide against Akt-1. 2016,  
20. Li H, Quan J, Zhang M, Yung B C, Cheng X, Liu Y, et al. Lipid-
Albumin Nanoparticles (LAN) for Therapeutic Delivery of 
Antisense Oligonucleotide against HIF-1alpha. Mol Pharm. 2016, 
13: 2555-2562; doi: 10.1021/acs.molpharmaceut.6b00363. 
21. Chen Y, Bian Y, Sun Y, Kang C, Yu S, Fu T, et al. Identification 
of 4-aminoquinoline core for the design of new cholinesterase 
inhibitors. PeerJ. 2016, 4: e2140 
22. Davis M E. Design and development of IT-101, a cyclodextrin-
containing polymer conjugate of camptothecin. Advanced drug 
delivery reviews. 2009, 61: 1189-1192 
23. Guo X K, Sun H P, Shen S, Sun Y, Xie F L, Tao L, et al. 
Synthesis and evaluation of gambogic acid derivatives as 
antitumor agents. Part III. Chemistry & biodiversity. 2013, 10: 
73-85 
24. Liu Z-l, Zhang R-m, Meng Q-g, Zhang X-c, and Sun Y. 
Discovery of new protein kinase CK2 inhibitors with 1, 3-dioxo-
2, 3-dihydro-1 H-indene core. MedChemComm. 2016, 7: 1352-
1355 
25. Sun H, Zhu J, Chen Y, Sun Y, Zhi H, Li H, et al. Docking Study 
and Three‐ Dimensional Quantitative Structure‐ Activity 
Relationship (3D‐ QSAR) Analyses and Novel Molecular Design 
of a Series of 4‐ Aminoquinazolines as Inhibitors of Aurora B 
Kinase. Chinese Journal of Chemistry. 2011, 29: 1785-1799 
26. Qian W-Y, Sun D-M, Zhu R-R, Du X-L, Liu H, and Wang S-L. 
pH-sensitive strontium carbonate nanoparticles as new anticancer 
vehicles for controlled etoposide release. Int J Nanomed. 2012, 7: 
5781-5792 
27. Wang Y, Dou L, He H, Zhang Y, and Shen Q. Multifunctional 
nanoparticles as nanocarrier for vincristine sulfate delivery to 
overcome tumor multidrug resistance. Molecular pharmaceutics. 
2014, 11: 885-894 
28. Liu F, Sun Y, Kang C, and Zhu H. Pegylated Drug Delivery 
Systems: From Design to Biomedical Applications. Nano LIFE. 
2016, 6: 1642002 
29. Qiao H, Fang D, Chen J, Sun Y, Kang C, Di L, et al. Orally 
delivered polycurcumin responsive to bacterial reduction for 
targeted therapy of inflammatory bowel disease. Drug Delivery. 
2017, 24: 233-242 
30. Song L, Kang C, Sun Y, Huang W, Liu W, and Qian Z. Crocetin 
Inhibits Lipopolysaccharide-Induced Inflammatory Response in 
Human Umbilical Vein Endothelial Cells. Cellular Physiology 
and Biochemistry. 2016, 40: 443-452 
31. XU S-h, Chen K, CHEN M-l, ZHOU P-p, HE G-w, CUI Y-j, et 
al. Dynamic expression of AQP4 in early stageof 
ischemia/reperfusion rats and cerebral edema. Chinese 
Pharmacological Bulletin. 2016: 1433-1441 
32. Xue X, Zhao N-Y, Yu H-T, Sun Y, Kang C, Huang Q-B, et al. 
Discovery of novel inhibitors disrupting HIF-1α/von Hippel–
Lindau interaction through shape-based screening and cascade 
docking. PeerJ. 2016, 4: e2757 
33. Shin J-Y, Yang Y, Heo P, Lee J-C, Kong B, Cho J Y, et al. pH-
responsive high-density lipoprotein-like nanoparticles to release 
paclitaxel at acidic pH in cancer chemotherapy. Int J 
Nanomedicine. 2012, 7: 2805-2816 
34. Han R, Sun Y, Kang C, Sun H, and Wei W. Amphiphilic 
dendritic nanomicelle-mediated co-delivery of 5-fluorouracil and 
doxorubicin for enhanced therapeutic efficacy. Journal of Drug 
Targeting. 2017, 25: 140-148 
35. Yang Z, Xie J, Zhu J, Kang C, Chiang C, Wang X, et al. 
Functional exosome-mimic for delivery of siRNA to cancer: in 
vitro and in vivo evaluation. Journal of Controlled Release. 2016, 
243: 160-171 
36. Yao Z, Sun Y, and Kang C. Structure and Self-Assembly of 
Multicolored Naphthalene Diimides Semiconductor. Nano LIFE. 
2016, 6: 1642007 
37. Zhong X, Sun Y, Kang C, and Wan G. The theory of 
dielectrophoresis and its applications on medical and materials 
research. European Journal of BioMedical Research. 2017, 2: 7-
11 
38. Du J-Z, Du X-J, Mao C-Q, and Wang J. Tailor-made dual pH-
sensitive polymer–doxorubicin nanoparticles for efficient 
anticancer drug delivery. Journal of the American Chemical 
Society. 2011, 133: 17560-17563 
 
